Pharmacy Robotics and Automation Vendor Security Risk Assessment Checklist

Pharmacy robotics and automation systems can connect dispensing equipment, pharmacy software, vendor support tools, and patient information. Use this checklist to evaluate how a vendor protects those systems, supports safe operations, and responds when risks or disruptions arise.

How to assess vendor security governance and access controls

Start by identifying which vendor services and subcontractors can access your systems or protected health information (PHI). If the vendor creates, receives, maintains, or transmits electronic PHI on your behalf, assess whether a HIPAA business associate agreement is required and ensure the agreement defines permitted uses, safeguards, subcontractor obligations, and incident reporting. HHS explains the applicable business associate requirements.

• Ask who is accountable for security, how vendor personnel are trained, and how access is approved, reviewed, and removed when roles change.
• Verify that individual users have unique accounts and permissions aligned with their job duties. Look for role-based access control, least privilege, and separate administrative accounts.
• Request multifactor authentication for remote access and privileged accounts. Treat it as a security control to evaluate for your environment—not as a HIPAA-specific, universal stand-alone requirement. The Security Rule requires access controls and person or entity authentication, while allowing security measures to be selected based on risk. See HHS’s HIPAA Security Rule summary.
• Determine whether vendor support access is disabled by default, approved for a defined period, logged, and limited to necessary systems. Ask how emergency access is authorized and reviewed afterward.
• Review the vendor’s security policies, subcontractor oversight, security risk assessment process, and history of material incidents or unresolved findings.

What to verify in pharmacy robotics software and system architecture

Ask for a current system architecture and data-flow overview covering the robotics equipment, control software, pharmacy systems, network connections, cloud services, and vendor support pathways. Confirm that the diagram reflects your proposed configuration rather than only a generic product model.

• Map interfaces, APIs, ports, remote connections, service accounts, and data exchanged with pharmacy or enterprise systems. Identify where PHI may appear, including support logs and diagnostic files.
• Review network segmentation and safeguards that limit the impact of a compromised workstation, service account, or robotics component.
• Ask how the system protects administrative interfaces, manages credentials, and prevents unauthorized configuration changes or dispensing workflow alterations.
• Verify how software and firmware updates are authenticated, tested, approved, and deployed, including rollback procedures if an update causes a disruption.
• Confirm the supported software versions, security update process, and end-of-support dates for each major component. Ask how the vendor communicates changes that could affect security or operations.
• Plan for safe operations during loss of network connectivity, central software, or vendor support. Document which pharmacy functions stop, which can continue, and how staff should switch to approved fallback procedures.

HIPAA’s technical safeguards address access control, audit controls, authentication, integrity, and transmission security for systems containing electronic PHI. Review the relevant 45 CFR § 164.312 technical safeguards against the system’s actual design.

How to evaluate data protection and patient information handling

Trace how patient and prescription information is collected, used, transmitted, stored, backed up, and deleted. Confirm whether the vendor can minimize PHI in telemetry, error reports, screenshots, and support tickets, and whether it can use de-identified or synthetic data for troubleshooting when practical.

• Ask for encryption protections for PHI in transit and at rest, plus details on key ownership, access, rotation, and recovery. HIPAA’s encryption implementation specifications are addressable, so assess the vendor’s safeguards and documented risk rationale rather than assuming one configuration is universally mandated.
• Review retention periods, deletion procedures, backup retention, data locations, and how the vendor handles data at contract termination.
• Check whether staff can access records through support tools, and whether access is limited, logged, and available for review by the pharmacy.
• Confirm that the vendor’s agreements and operating practices cover subcontractors that handle PHI. HHS notes that business associate arrangements must address appropriate safeguards and applicable downstream subcontractors in its business associate guidance.
• Ask how the vendor detects and prevents PHI from being exposed in diagnostic logs, notifications, analytics, or test environments.

What to check for vulnerability management and security testing

Assess whether the vendor can identify vulnerabilities in its own software and third-party components, determine their relevance to your deployment, and communicate and remediate risks in a timely way.

• Request a current software bill of materials (SBOM) or an equivalent component inventory for the software supporting the system. Ask how it is updated and used to identify affected components. NIST describes SBOMs as a way to improve software supply-chain transparency and vulnerability identification in its software supply-chain guidance.
• Ask for summaries of recent penetration tests and vulnerability assessments, including scope, date, material findings, remediation status, and any exclusions. Request evidence that testing covers relevant interfaces and remote support pathways.
• Review the vendor’s vulnerability disclosure process: how researchers and customers report issues, how the vendor triages and communicates them, and how it issues security updates. NIST provides recommendations for handling and communicating vulnerability reports in its vulnerability disclosure guidance.
• Agree on contractual expectations for critical vulnerability notification, remediation updates, and coordination with your pharmacy’s security team. Evaluate proposed timelines against clinical and operational risk.
• If the product is an FDA-regulated “cyber device,” verify which FDA cybersecurity requirements apply to that product and manufacturer. FDA guidance identifies SBOM and postmarket vulnerability-management considerations for applicable devices; do not assume those device-specific requirements apply to every pharmacy automation system. See the FDA medical device cybersecurity resources.

How to assess incident response and business continuity

Ask the vendor to describe how it detects, contains, investigates, and recovers from security incidents that affect the robotics system, vendor support environment, or PHI. Confirm that your pharmacy knows whom to contact and what information the vendor will provide during an investigation.

• Review incident response procedures, escalation contacts, evidence preservation practices, and how the vendor coordinates with your security, pharmacy operations, privacy, and legal teams.
• Make sure the contract and any business associate agreement specify how and when incidents are reported, how updates are delivered, and how the vendor will support your investigation. HHS describes business associate security incident reporting obligations in its security incident guidance.
• Request business continuity and disaster recovery plans that address system outages, cyberattacks, equipment failure, and loss of connectivity. Check recovery objectives, restoration dependencies, and how the vendor will keep you informed.
• Request evidence of disaster recovery testing, including the date, scenarios exercised, identified gaps, and corrective actions. HHS describes contingency planning—including backup, recovery, emergency operations, and periodic testing—in its ransomware and HIPAA guidance.
• Agree on pharmacy-specific downtime and manual fallback procedures. Verify how staff can continue or safely pause essential workflows, reconcile activity after recovery, and escalate risks to patient care.

What evidence should vendors provide during a security review

Request evidence that is relevant to the specific product, service, deployment, and data access being assessed. Protect confidential reports appropriately, but do not treat a policy statement or a general assurance of “HIPAA compliance” as a substitute for product-specific evidence.

• A completed security questionnaire and an overview of the vendor’s security governance, risk management, and subcontractor oversight.
• A system architecture diagram, data-flow description, integration inventory, and details of remote support access.
• Access-control and authentication details, including role definitions, unique user accounts, multifactor authentication options, privileged access safeguards, and audit logging.
• PHI handling documentation covering data minimization, encryption, retention, deletion, backups, and subcontractor access.
• A current SBOM or component inventory, software support lifecycle, vulnerability disclosure process, and summaries of relevant security testing and remediation.
• Incident response and business continuity documentation, plus a summary of recent recovery exercises and disaster recovery testing.
• Independent assessment reports or certifications the vendor actually holds, with their scope, validity period, and any exceptions clearly identified. Ask for corrective-action evidence where findings are relevant.
• The proposed business associate agreement, service-level terms, incident notification provisions, security responsibilities, and end-of-contract data return or deletion terms, where applicable.

A strong review ties vendor evidence to your pharmacy’s risk analysis, system configuration, and operational needs. Reassess when a significant change, incident, new integration, or material vulnerability changes the risk; HHS states that the Security Rule does not set one universal risk-analysis frequency and that reviews should be updated as needed in its risk analysis guidance.

FAQs

What security documents should a pharmacy automation vendor provide?

Request a security questionnaire, system architecture and data-flow diagrams, access-control details, PHI handling practices, incident response and continuity plans, a current SBOM or component inventory, vulnerability management and testing summaries, and applicable independent assessment reports. Also review the proposed business associate agreement when the vendor’s role requires one.

How should a pharmacy assess vendor access to protected health information?

Map what PHI the vendor can access and why, including information in support tools and diagnostic files. Verify unique accounts, role-based access, least privilege, multifactor authentication for remote or privileged access, approval and logging of support sessions, periodic access review, and prompt access removal when no longer needed.

What security controls should pharmacy robotics systems support?

Evaluate access controls, unique user identification, authentication, audit logging, secure data transmission, integrity protections, controlled updates, vulnerability management, and safeguards for vendor remote access. Consider encryption, multifactor authentication, network segmentation, and downtime procedures based on your risk analysis and system design.

How often should a pharmacy reassess its automation vendor’s security?

HIPAA does not specify one universal interval for reassessment. Set a risk-based review schedule—such as an annual checkpoint if appropriate—and reassess sooner after significant system or vendor changes, a security incident, a new integration, or a material vulnerability. HHS advises that risk analysis should be ongoing and updated as needed.